Drugs / MUC1-gene-DC-CTL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02602249 | Oct 2017 → Apr 2019 | gastric cancer | Beijing Doing Biomedical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUC1-gene-DC-CTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02602249 ↗ |
| Modality | Cell therapy | “Antigen-specific Cytotoxic T Lymphocytes Induced by Dendritic Cells” NCT02602249 ↗ |
| Route | Other | “which will be infused to the patients as immunotherapy.” NCT02602249 ↗ |